Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: based on the SONIA trial
This study supports the early use of CDK4/6 inhibitors combined with endocrine therapy as a cost-effective strategy for advanced HR+/HER2- breast cancer in China. Continued real-world monitoring is needed to adapt to changes in drug pricing and clinical practice.
Authors
- Xiaohu Jin (ORCID: https://orcid.org/0000-0001-6436-1081)
- Zhifeng Li (ORCID: https://orcid.org/0000-0003-3908-0012)
Institutions
- Nantong University (CN)
- Affiliated Hospital of Nantong University (CN)
- Second People's Hospital of NanTong (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-11-26
- DOI
- https://doi.org/10.3389/fphar.2025.1700291
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00